Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$64.42 USD
+1.22 (1.93%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $64.96 +0.54 (0.84%) 7:44 PM ET
3-Hold of 5 3
B Value C Growth B Momentum C VGM
Cash flow Statements
Fiscal Year End for Halozyme Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 281.59 | 202.13 | 402.71 | 129.09 | -72.24 |
Depreciation/Amortization & Depletion | 85.84 | 58.59 | 8.90 | 18.26 | 4.08 |
Net Change from Assets/Liabilities | -38.67 | -88.45 | 2.24 | -107.85 | -54.54 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 59.81 | 67.84 | -114.41 | 15.96 | 37.27 |
Net Cash From Operating Activities | 388.57 | 240.11 | 299.44 | 55.45 | -85.42 |
Property & Equipment | -15.29 | 21.20 | -1.46 | -1.43 | -4.04 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -999.12 | 0.00 | 0.00 | 0.00 |
Investments | -81.62 | 490.92 | -404.83 | 79.78 | -1.51 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -96.91 | -487.01 | -406.29 | 78.35 | -5.55 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -394.50 | -185.95 | -337.52 | -86.72 | -185.77 |
Issuance (Repayment) of Debt | -13.48 | 555.43 | 415.81 | -19.56 | 339.27 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | -7.10 | -0.42 | 0.00 | -0.28 |
Net Cash from Financing Activities | -407.99 | 362.37 | 77.87 | -106.28 | 153.22 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -116.33 | 115.48 | -28.98 | 27.52 | 62.24 |
Cash at Beginning of Period | 234.70 | 119.22 | 148.20 | 120.68 | 58.44 |
Cash at End of Period | 118.37 | 234.70 | 119.22 | 148.20 | 120.68 |
Diluted Net EPS | 2.10 | 1.44 | 2.74 | 0.91 | -0.50 |
Fiscal Year End for Halozyme Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 170.07 | 76.82 | 281.59 | 196.21 | 114.37 |
Depreciation/Amortization & Depletion | 38.80 | 19.67 | 85.84 | 65.81 | 42.40 |
Net Change from Assets/Liabilities | -60.71 | 21.56 | -38.67 | -15.15 | -37.07 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 37.06 | 11.38 | 59.81 | 39.36 | 34.11 |
Net Cash From Operating Activities | 185.22 | 129.43 | 388.57 | 286.22 | 153.81 |
Property & Equipment | -6.13 | -3.55 | -15.29 | -12.70 | -9.75 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -118.59 | -79.14 | -81.62 | -75.92 | 4.59 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -124.72 | -82.68 | -96.91 | -88.62 | -5.17 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 8.99 | 0.00 | -394.50 | -144.58 | -148.69 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | -13.48 | -13.48 | -13.48 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | -0.49 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 8.99 | -0.49 | -407.99 | -158.07 | -162.17 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 69.49 | 46.26 | -116.33 | 39.53 | -13.53 |
Cash at Beginning of Period | 118.37 | 118.37 | 234.70 | 234.70 | 234.70 |
Cash at End of Period | 187.86 | 164.63 | 118.37 | 274.23 | 221.17 |
Diluted Net EPS | 0.72 | 0.60 | 0.64 | 0.61 | 0.56 |